Perigard-D 4mg/1.25mg Tablet
By Perigard-D
Rx
10 Tablet in a Strip

Composition
Perindopril erbumine(4mg) + Indapamide(1.25mg)

Manufacturer - Glenmark Pharmaceuticals Ltd
Glenmark Pharmaceuticals Limited, B/2, Mahalaxmi Chambers, 22, Bhulabhai Desai Road, Mumbai – 400 026.

Expires on or after
August, 2025

liver
When it comes to liver disease, caution is essential when using Perigard-D 4mg/1.25mg Tablet. Patients with liver issues should be careful and seek advice from their doctor before taking this medication. It might be necessary to adjust the dosage of Perigard-D 4mg/1.25mg Tablet in such cases. It is important to consult with your healthcare provider to ensure the safe and appropriate use of this tablet if you have liver disease.

kidney
Perigard-D 4mg/1.25mg Tablet requires caution for patients with kidney disease. Dosage adjustments may be necessary. Consult your doctor if you have renal impairment.

alcohol
Perigard-D 4mg/1.25mg Tablet can lead to increased drowsiness when combined with alcohol.

driving
Perigard-D 4mg/1.25mg Tablet might impact your driving ability. While it typically does not affect alertness, some patients may experience dizziness or weakness from low blood pressure, which can hinder driving.

pregnancy
Perigard-D 4mg/1.25mg Tablet is not recommended during pregnancy due to potential risks to the developing baby. Your doctor may only prescribe it in critical situations where benefits outweigh risks. Consult your doctor before use.

breastfeeding
Perigard-D 4mg/1.25mg Tablet is likely safe during breastfeeding based on minimal data showing no significant risk to the baby.
Habit Forming | No |
Chemical Class | - |
Therapeutic Class | - |
Action Class | - |
₹98
Inclusive of all taxes
Content verified by

Dr. Preeti Kumar
MBBS, DGO - Obstetrics and Gynaecology, DNB - Obstetrics and Gynaecology
Last update on 01-Oct-2024